Low plasma levels of BTLA and LAG-3 before HCV therapy are associated with metabolic disorders after HCV eradication in persons with HIV/HCV coinfection: a retrospective study
We discovered that low plasma levels of BTLA and LAG-3 before HCV therapy significantly correlate with an increased risk of developing metabolic disorders after treatment.
Authors
- Ana Virseda‐Berdices (ORCID: https://orcid.org/0000-0002-9549-567X)
- Rubén Martín‐Escolano (ORCID: https://orcid.org/0000-0002-6262-9344)
- Salvador Resino (ORCID: https://orcid.org/0000-0001-8783-0450)
- Víctor Hontañón (ORCID: https://orcid.org/0000-0003-3070-2647)
- Oscar Brochado‐Kith (ORCID: https://orcid.org/0000-0001-8372-2604)
- Juan Berenguer (ORCID: https://orcid.org/0000-0001-8541-8200)
- Cristina Díez (ORCID: https://orcid.org/0000-0002-3508-9979)
- María Ángeles Jiménez‐Sousa (ORCID: https://orcid.org/0000-0002-1945-6169)
- Juan González‐García (ORCID: https://orcid.org/0000-0002-3652-002X)
- Amanda Fernández-Rodríguez
Institutions
- Hospital Universitario La Paz (ES)
- Instituto de Salud Carlos III (ES)
- Hospital General Universitario Gregorio Marañón (ES)
- Centro Nacional de Microbiologia (ES)
- Hospital La Paz Institute for Health Research (ES)
- Centro de Investigación Biomédica en Red (ES)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2024-10-28
- DOI
- https://doi.org/10.3389/fphar.2024.1341612
- Citations
- 1
- Primary Topic
- Metabolism, Diabetes, and Cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.23
Funders
- Comunidad de Madrid
- Ministerio de Ciencia e Innovación
- Instituto de Salud Carlos III
- European Regional Development Fund
- Agencia Estatal de Investigación